Abstract 102P
Background
Vulvar cancer is a rare disease with increasing incidence. Treatment can involve surgery and chemoradiation for local and regional disease, while systemic chemotherapy and immunotherapy are reserved for patients with distant metastases. Patients with unresectable or metastatic disease have relatively poor outcomes. Cisplatin and radiation (cis-RT) have been reported to have anti-tumor immunomodulatory properties in addition to their cytotoxic effects. We evaluated the addition of pembrolizumab (pembro) to cis-RT in vulvar cancer.
Methods
In this ongoing single-arm phase II trial (NCT04430699), patients with primary unresectable, incompletely resected, recurrent, or metastatic squamous cell carcinoma of the vulva undergoing RT were eligible. Patients who had received prior chemotherapy or immunotherapy were also eligible. Patients received cis 40 mg/m2 weekly concurrently with RT, and pembro 200 mg was administered every three weeks for a total of 12 cycles. The primary endpoint was ORR, and the secondary objective was 6-month RFS. Serum cytokines and HMGB-1 were assessed.
Results
At the time of the data cutoff, 15 patients were enrolled, and 14 were evaluable. Any grade adverse events (AE) occurred in all patients. Grade (G) 3 AEs occurred in 11 (78.6%) patients, most of which were related to cis. There were no G4 or higher AEs. There was one serious AE; a G3 acute kidney injury related to cis. G3 neutropenia and G3 ALT increase were observed in 4 (28.6%) and 1 (7.1%) patient respectively. The most common treatment-emergent adverse events (TEAE) were anemia (78.6%), diarrhea (78.6%), nausea (78.6%), fatigue (78.6%), and thrombocytopenia (50%). 18 AEs were related to pembro, and all were grade 1, except for G2 nephrotic syndrome in 1 patient (9%) and G2 hypothyroidism in 2 patients (14%). Patients with progressive disease were more likely to have elevated serum levels of CCL4, CCL11, and CXCL12 at cycle 3.
Conclusions
In this interim analysis, concurrent treatment with cis-RT and pembro did not lead to any unexpected AEs. Cytokine analysis might yield insight into the mechanisms of resistance. This study, the first to evaluate pembrolizumab with cis-RT, is ongoing, with a target enrollment of 24 patients.
Clinical trial identification
NCT04430699.
Legal entity responsible for the study
The authors.
Funding
Merck Sharp & Dohme Corporation.
Disclosure
O.O. Yeku: Financial Interests, Personal, Advisory Board: hC Bioscience; Financial Interests, Personal, Speaker, Consultant, Advisor: TigaTx Inc, GIMV NV; Other, Institutional, Principal Investigator: Merck Sharp & Dohme Corp, Avant Immunotherapeutics, Compugen, Ascendis Pharma A/S, ProfoundBio, Avenge Bio, Immunocore Limited, Duality Biologics; Financial Interests, Institutional, Principal Investigator: Department of Defense. S. Bouberhan: Financial Interests, Personal, Speaker, Consultant, Advisor: ImmunoGen. C.M. Castro: Financial Interests, Personal, Speaker, Consultant, Advisor: Qiagen, Teladoc, Aikili Biosystems, InfiniteMD. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to Cabozantinib (CABO) plus Durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the Phase 2 ARCADIA trial)
Presenter: Veronica Huber
Session: Poster Display
27P - Peripheral biomarker analysis in patients with advanced urothelial carcinoma (UC) after platinum chemotherapy treated with Cabozantinib (CABO) plus Durvalumab (DURVA): preliminary analysis from the Phase 2 ARCADIA trial.
Presenter: Francesco Sgambelluri
Session: Poster Display
28P - 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
Presenter: Frank Stenner-Liewen
Session: Poster Display
30P - CD4+ T cells within the tumor microenvironment are an independent predictor of recurrence, but do not improve the performance of a predictive model in oral squamous cell carcinoma
Presenter: Sangeeta Bisheshar
Session: Poster Display
31P - Characterization of pre-exhausted / exhausted state of CD8+ T cells in HRAS mutant head and neck carcinomas (HNSCCs). Implications for response to immune checkpoint blockade (ICB).
Presenter: Ioannis Kotsantis
Session: Poster Display
32P - Tumor-agnostic plasma assay for circulating tumor DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor
Presenter: Natasha Honoré
Session: Poster Display
34P - Heterogeneous response to Immune Checkpoint Inhibitors in metastatic melanoma patients - assessment of lesion-level response with 18F-FDG PET/CT
Presenter: Katja Strasek
Session: Poster Display